Suppr超能文献

进展期胃癌完全腹腔镜根治性胃切除术的可行性与安全性:与早期胃癌的比较

Feasibility and Safety of Totally Laparoscopic Radical Gastrectomy for Advanced Gastric Cancer: Comparison with Early Gastric Cancer.

作者信息

Lee Seungyeob, Lee Hayemin, Lee Junhyun

机构信息

Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

J Gastric Cancer. 2018 Jun;18(2):152-160. doi: 10.5230/jgc.2018.18.e17. Epub 2018 Jun 22.

Abstract

PURPOSE

Totally laparoscopic gastrectomy (TLG) for advanced gastric cancer (AGC) is a technically and oncologically challenging procedure for surgeons. This study aimed to compare the oncologic feasibility and technical safety of TLG for AGC versus early gastric cancer (EGC).

MATERIALS AND METHODS

Between 2011 and 2016, 535 patients (EGC, 375; AGC, 160) underwent curative TLG for gastric cancer. Clinicopathologic characteristics and surgical outcomes of both patient groups were analyzed and compared.

RESULTS

Patients with AGC required a longer operation time and experienced more intraoperative blood loss than those with EGC did. However, patients from both the AGC and EGC groups demonstrated similar short-term surgical outcomes such as postoperative morbidity (14.4% vs. 13.3%, P=0.626), mortality (0% vs. 0.5%, P=0.879), time-to-first oral intake (2.7 days for both groups, P=0.830), and postoperative hospital stay (10.2 days vs. 10.1 days, P=0.886). D2 lymph node dissection could be achieved in the AGC group (95%), with an adequate number of lymph nodes being dissected (36.0±14.9). In the AGC group, the 3-year overall and disease-free survival rates were 80.5% and 73.7%, respectively.

CONCLUSIONS

TLG is as safe and effective for AGC as it is for EGC.

摘要

目的

对于外科医生而言,完全腹腔镜胃癌切除术(TLG)治疗进展期胃癌(AGC)在技术和肿瘤学方面都具有挑战性。本研究旨在比较TLG治疗AGC与早期胃癌(EGC)的肿瘤学可行性和技术安全性。

材料与方法

2011年至2016年间,535例患者(EGC 375例,AGC 160例)接受了根治性TLG治疗胃癌。分析并比较了两组患者的临床病理特征和手术结果。

结果

与EGC患者相比,AGC患者手术时间更长,术中失血更多。然而,AGC组和EGC组患者的短期手术结果相似,如术后发病率(14.4%对13.3%,P = 0.626)、死亡率(0%对0.5%,P = 0.879)、首次经口进食时间(两组均为2.7天,P = 0.830)和术后住院时间(10.2天对10.1天,P = 0.886)。AGC组可实现D2淋巴结清扫(95%),清扫淋巴结数量充足(36.0±14.9)。AGC组3年总生存率和无病生存率分别为80.5%和73.7%。

结论

TLG治疗AGC与治疗EGC一样安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4643/6026707/20a9fbe55874/jgc-18-152-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验